DE60231616D1 - Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i - Google Patents

Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i

Info

Publication number
DE60231616D1
DE60231616D1 DE60231616T DE60231616T DE60231616D1 DE 60231616 D1 DE60231616 D1 DE 60231616D1 DE 60231616 T DE60231616 T DE 60231616T DE 60231616 T DE60231616 T DE 60231616T DE 60231616 D1 DE60231616 D1 DE 60231616D1
Authority
DE
Germany
Prior art keywords
treatment
illness
prevention
sexually
transferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231616T
Other languages
English (en)
Inventor
Barry Ross Matthews
George Holan
Peter Karellas
Scott Andrew Henderson
David Francis O'keefe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Starpharma Pty Ltd
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Application granted granted Critical
Publication of DE60231616D1 publication Critical patent/DE60231616D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure
DE60231616T 2001-03-30 2002-03-28 Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i Expired - Lifetime DE60231616D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR4128A AUPR412801A0 (en) 2001-03-30 2001-03-30 Agent for the prevention and treatment of sexually transmitted disease s - I
PCT/AU2002/000407 WO2002079299A1 (en) 2001-03-30 2002-03-28 Agent for the prevention and treatment of sexually transmitted diseases-i

Publications (1)

Publication Number Publication Date
DE60231616D1 true DE60231616D1 (de) 2009-04-30

Family

ID=3828128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231616T Expired - Lifetime DE60231616D1 (de) 2001-03-30 2002-03-28 Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i

Country Status (15)

Country Link
US (2) US7589056B2 (de)
EP (1) EP1399499B1 (de)
JP (1) JP4216076B2 (de)
KR (1) KR100882343B1 (de)
CN (1) CN1305931C (de)
AT (1) ATE426001T1 (de)
AU (2) AUPR412801A0 (de)
BR (1) BRPI0208411B8 (de)
CA (1) CA2441357C (de)
DE (1) DE60231616D1 (de)
ES (1) ES2324600T3 (de)
HK (1) HK1064108A1 (de)
MX (1) MXPA03008909A (de)
NZ (1) NZ528230A (de)
WO (1) WO2002079299A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN1778967B (zh) * 2004-11-25 2010-11-10 中国科学院化学研究所 抑制hiv-1反式激活蛋白与反式激活应答序列rna结合用的聚酰胺-胺型树状化合物
KR20140027528A (ko) * 2005-10-18 2014-03-06 스타파마 피티와이 리미티드 살미생물성 덴드리머 조성물 전달 시스템
ES2937113T3 (es) 2006-01-20 2023-03-24 Starpharma Pty Ltd Macromolécula modificada
AU2007229268B2 (en) * 2006-03-22 2013-01-10 Starpharma Pty Limited Contraceptive composition
PL2052011T3 (pl) * 2006-08-11 2021-03-08 Starpharma Pty Limited Nakierowany środek terapeutyczny będący dendrymerem polilizynowym
EP2076557A4 (de) * 2006-08-11 2012-08-29 Starpharma Pty Ltd Polylysindendrimer-kontrastmittel
JP2008202025A (ja) * 2007-01-22 2008-09-04 Honda Motor Co Ltd プロトン伝導性高分子
JP2008270177A (ja) 2007-03-23 2008-11-06 Honda Motor Co Ltd プロトン伝導体
IT1395137B1 (it) 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
US8251452B2 (en) * 2009-11-13 2012-08-28 Hill Jason D Gaming chairs
RU2632110C2 (ru) 2011-05-16 2017-10-02 Старфарма Пти Лтд Способ лечения или профилактики бактериального вагиноза
CN105007910B (zh) * 2012-09-13 2019-03-19 星法马有限公司 眼部感染的治疗或预防药物的制造用途
US20210030785A1 (en) * 2016-05-05 2021-02-04 Starpharma Pty Ltd. Method of prophylaxis of zika virus infection
CN108676067B (zh) * 2018-03-23 2019-09-06 广州朗圣药业有限公司 一种预防hiv感染的新化合物及其制备方法
JP2021529818A (ja) * 2018-07-19 2021-11-04 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
CN114053392A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗hpv感染的药物中的应用
CN114053394A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN114053393A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 一种药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) * 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
AUPM623994A0 (en) 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
US7572459B2 (en) * 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
AUPP584398A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Inhibition of toxic materials or substances
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
AU779140B2 (en) * 1999-11-18 2005-01-06 Exxon Chemical Patents Inc. Method for the synthesis of molecular sieves
US6893506B2 (en) * 2002-03-11 2005-05-17 Micron Technology, Inc. Atomic layer deposition apparatus and method

Also Published As

Publication number Publication date
BR0208411A (pt) 2004-03-30
KR20040027506A (ko) 2004-04-01
JP2004532211A (ja) 2004-10-21
US20090269298A1 (en) 2009-10-29
US20050008611A1 (en) 2005-01-13
NZ528230A (en) 2006-02-24
AU2002245932B2 (en) 2007-04-05
AUPR412801A0 (en) 2001-05-03
ES2324600T3 (es) 2009-08-11
CN1503816A (zh) 2004-06-09
EP1399499A1 (de) 2004-03-24
CA2441357A1 (en) 2002-10-10
EP1399499A4 (de) 2004-09-29
BRPI0208411B1 (pt) 2016-06-28
HK1064108A1 (en) 2005-01-21
WO2002079299A1 (en) 2002-10-10
US7589056B2 (en) 2009-09-15
CA2441357C (en) 2011-05-31
MXPA03008909A (es) 2005-03-07
BRPI0208411B8 (pt) 2021-05-25
US8158575B2 (en) 2012-04-17
CN1305931C (zh) 2007-03-21
KR100882343B1 (ko) 2009-02-12
JP4216076B2 (ja) 2009-01-28
ATE426001T1 (de) 2009-04-15
EP1399499B1 (de) 2009-03-18

Similar Documents

Publication Publication Date Title
DE60231616D1 (de) Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i
DE60135732D1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE60117043D1 (de) Behandlung von mukositis
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
BR0210335A (pt) Copolìmero de blocos, e, composição
ATE382700T1 (de) Wasch- und reinigungsmittel mit hybrid-alpha- amylasen
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
PL375621A1 (en) Pharmaceutical compositions comprising flavonoids and menthol
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
BR0201889A (pt) Vacinas de ige não-anafilactogênicas
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
SE0003126D0 (sv) Method of treatment
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE421326T1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition